RBII (Rising BioSciences PNK) falls 99% to $0.000001 on 10 Mar 2026: liquidity alert

RBII stock plunged 99.00% to $0.000001 (scientific: $1.00e-06) on 10 Mar 2026 during market hours, driven by an outsized volume spike of 2,230,000.00 shares. This sharp move makes Rising BioSciences, Inc. (RBII) one of today’s top losers on the PNK exchange in the United States (USD). Traders should note the extremely low market cap of $499.00 and the thin 50-day average price of $0.00001, which magnify volatility and liquidity risk for RBII stock.

RBII stock price action and market data

RBII stock closed the session at $0.000001 with a one-day change of -99.00% and a trade volume of 2,230,000.00 shares. The stock’s average volume is 1,033.00, so today’s relative volume was extremely high and suggests forced selling or speculative trading. Rising BioSciences, Inc. trades on the PNK exchange in the United States and shows a shares outstanding figure of 499,145,000.00, creating structural liquidity constraints.

Why RBII fell: catalysts and sector context

The immediate driver is likely market microstructure rather than a single news release; Investing.com lists general company updates and the broader earnings calendar that may have increased selling pressure source source. Healthcare small-caps, especially in Medical – Pharmaceuticals, can move violently when thin trading meets negative flows. Sector peers in healthcare were mixed, but RBII’s tiny market cap and low float amplified downside.

RBII financials and valuation metrics

Rising BioSciences reports a market cap of $499.00, revenue per share TTM of 0.00073819, and negative operating cash flow per share of -0.00007. The company shows a book value per share of -0.00103, current ratio TTM of 0.12, and enterprise value of 1,008,770.00, reflecting balance sheet strain and unusual EV/market cap dynamics. These metrics point to elevated solvency and valuation risk for RBII stock.

Technicals, liquidity and trading risks for RBII stock

Technicals are unreliable for RBII stock given the near-zero price. Key indicators show RSI 46.37, ADX 10.16 (no trend) and an OBV reading of -3,542,142.00, signaling heavy distribution. With a 50-day price average of $0.00001 and 200-day average $0.00003, sudden spikes in volume can create outsized percent moves and order execution problems for retail traders.

Meyka AI grade, analyst view and actionable metrics for RBII stock

Meyka AI rates RBII with a score out of 100: Score: 65.07 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Our analysis flags low market cap ($499.00), thin liquidity, negative working capital (-1,521,473.00) and stretched enterprise value as primary risk drivers for RBII stock.

Final Thoughts

Key takeaways: RBII stock is a top loser on 10 Mar 2026 after collapsing 99.00% to $0.000001 on volume of 2,230,000.00 shares. Financial metrics show strained liquidity (current ratio 0.12) and negative cash flow per share (-0.00007), while market cap is only $499.00, increasing the chance of outsized percentage moves. Meyka AI’s forecast model projects $0.00 for the near term, implying an effective downside of -100.00% from the current quote; forecasts are model-based projections and not guarantees. Traders should treat RBII as a highly speculative, low-liquidity security and consider alternative healthcare exposure if seeking the sector. For real-time monitoring use the Meyka AI-powered market analysis platform and refer to official company filings before acting. Sources: Investing.com company news and earnings calendar for market context source source.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.